Vertex Pharmaceuticals Inc $ 264 -1.39 (-0.52%)
Warning! GuruFocus has detected 2 Medium warning signs with VRTX. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for VRTX (Vertex Pharmaceuticals Inc) from 1991 to Sep 22 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Vertex Pharmaceuticals stock (VRTX) PE ratio as of Sep 22 2020 is 33.33. More Details
Vertex Pharmaceuticals PE Ratio (TTM) Historical Data
View and export this data going back to 1991. Start your Free Trial
Vertex Pharmaceuticals PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:REGN NAS:SGEN NAS:MRNA NAS:ALXN NAS:INCY NAS:BMRN NAS:ALNY NAS:SRPT NAS:NBIX NAS:BNTX OCSE:NOVO B ASX:CSL XKRX:207940 XKRX:068270 HKSE:02269 OCSE:GMAB HKSE:01177 SZSE:300122 XBRU:UCB XAMS:GLPG
Traded in other countries VRTX.Austria VRTX34.Brazil VX1.Germany VRTX.Mexico VRTX.Switzerland 0QZU.UK VRTX.USA
Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex's pipeline also includes therapies for cancer, pain, inflammatory diseases, influenza, and other rare diseases.